It's open season for Mylan's EpiPen as Sanofi, Teva stumble

Last week, Sanofi ($SNY) pulled the main competitor to Mylan's ($MYL) EpiPen--Auvi-Q--from the market on concerns that the pens might be delivering inaccurate doses. Generics maker Teva ($TEVA) also said it won't be in a position to win approval for its copy until the second half of next year. The result? Open season for Mylan on the epinephrine injection market, of which Bernstein analyst Ronny Gal thinks the company can capture about 95%. More from FiercePharmaMarketing

Suggested Articles

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.